Hepatotoxicity Related to Protein Kinase Inhibitors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Although protein kinase inhibitors (PKIs) have proved effective in treating many cancers, few patients receiving PKIs may experience rare but life-threatening hepatotoxicity such as hepatic failure. Today, there is no large-scale retrospective pharmacovigilance study focusing on protein kinase inhibitors-related hepatotoxicity. The objective was to investigate reports of hepatotoxicity related to protein kinase inhibitors using FDA Adverse Event Reporting System (FAERS).
Epistemonikos ID: 605f98967208f8bb0b45a1b336266bf86ba1951a
First added on: May 13, 2024